CD19-targeted CAR T-cell therapy shows a 65% response rate in Richter transformation, with median progression-free survival of 8 months and overall survival of 14.4 months. Early response and age are ...

Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

Chimeric antigen receptor, or CAR, therapy is no longer just a cancer story. This review shows how the field is expanding beyond conventional CAR-T cells into a wider family of engineered cell ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

The new data bolster Allogene’s efforts to develop a new, easily administered cell therapy that could delay or prevent cancer recurrence.

CAR-T therapy has transformed treatment for some blood cancers, with seven FDA-approved products and strong clinical responses in hematologic malignancies. However, its limitations remain evident. In ...

A woman in her thirties who was dependent on blood transfusions and unresponsive to every standard treatment for her three ...

Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...